Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 824-832 |
| Journal | Journal of nuclear cardiology |
| Volume | 23 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 6 Jun 2016 |
Fingerprint
Keywords
- METIS-312257
- IR-99800
Cite this
}
Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA). / Reuvekamp, E.J.; Bulten, Ben; Nieuwenhuis, A.A.; Meekes, M.R.; de Haan, A.F.; Tol, J.; Maas, A.H.; Elias-Smale, S.E.; de Geus-Oei, Lioe-Fee.
In: Journal of nuclear cardiology, Vol. 23, No. 4, 06.06.2016, p. 824-832.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA)
AU - Reuvekamp, E.J.
AU - Bulten, Ben
AU - Nieuwenhuis, A.A.
AU - Meekes, M.R.
AU - de Haan, A.F.
AU - Tol, J.
AU - Maas, A.H.
AU - Elias-Smale, S.E.
AU - de Geus-Oei, Lioe-Fee
N1 - Open access
PY - 2016/6/6
Y1 - 2016/6/6
N2 - Background Trastuzumab is successfully used for the treatment of HER2-positive breast cancer. Because of its association with cardiotoxicity, LVEF is monitored by MUGA, though this is a relatively late measure of cardiac function. Diastolic dysfunction (DD) is believed to be an early predictor of cardiac impairment. We evaluate the merit of MUGA-derived diastolic function parameters in the early detection of trastuzumab-induced cardiotoxicity (TIC). Methods and Results 77 trastuzumab-treated patients with normal baseline systolic and diastolic function were retrospectively selected (n = 77). All serial MUGA examinations were re-analyzed for systolic and diastolic function parameters. 36 patients (47%) developed SD and 45 patients (58%) DD during treatment. Both systolic and diastolic parameters significantly decreased. Of the patients with SD, 24 (67%) also developed DD. DD developed prior to systolic impairment in 54% of cases, in 42% vice versa, while time to occurrence did not differ significantly (P = .52). This also applied to the subgroup of advanced stage breast cancer patients (P = .1). Conclusions Trastzumab-induced SD and DD can be detected by MUGA. An impairment of MUGA-derived diastolic parameters does not occur prior to SD and therefore cannot be used as earlier predictors of TIC.
AB - Background Trastuzumab is successfully used for the treatment of HER2-positive breast cancer. Because of its association with cardiotoxicity, LVEF is monitored by MUGA, though this is a relatively late measure of cardiac function. Diastolic dysfunction (DD) is believed to be an early predictor of cardiac impairment. We evaluate the merit of MUGA-derived diastolic function parameters in the early detection of trastuzumab-induced cardiotoxicity (TIC). Methods and Results 77 trastuzumab-treated patients with normal baseline systolic and diastolic function were retrospectively selected (n = 77). All serial MUGA examinations were re-analyzed for systolic and diastolic function parameters. 36 patients (47%) developed SD and 45 patients (58%) DD during treatment. Both systolic and diastolic parameters significantly decreased. Of the patients with SD, 24 (67%) also developed DD. DD developed prior to systolic impairment in 54% of cases, in 42% vice versa, while time to occurrence did not differ significantly (P = .52). This also applied to the subgroup of advanced stage breast cancer patients (P = .1). Conclusions Trastzumab-induced SD and DD can be detected by MUGA. An impairment of MUGA-derived diastolic parameters does not occur prior to SD and therefore cannot be used as earlier predictors of TIC.
KW - METIS-312257
KW - IR-99800
U2 - 10.1007/s12350-015-0164-x
DO - 10.1007/s12350-015-0164-x
M3 - Article
VL - 23
SP - 824
EP - 832
JO - Journal of nuclear cardiology
JF - Journal of nuclear cardiology
SN - 1071-3581
IS - 4
ER -